| CRC | EC | SST | Total |
---|---|---|---|---|
Number of individuals, n (%) | 78 (57.8%) | 33a (24.4%) | 24b (17.8%) | 135 (100%) |
Number of tumors tested, n (%) | 80 (58.4%) | 33 (24.1%) | 24 (17.5%) | 137 (100%) |
Study, n (%) | ||||
 ANGELS | 79 (98.7%) | 33 (100%) | 0 (0%) | 112 (81.8%) |
 MTS | 1 (1.3%)b | 0 (0%) | 24 (100%) | 25 (18.2%) |
Sex, n (%) | ||||
 Male | 40 (50%) | 0 (0%) | 20 (83.3%) | 60 (43.8%) |
 Female | 40 (50%) | 33 (100%) | 4 (16.7%) | 77 (56.2%) |
Age at diagnosis | ||||
 Mean ± SD | 47.4 ± 13.2 | 61.0 ± 9.3 | 65.2 ± 10.7 | 53.8 ± 14.1 |
 Min.—Max | 24–74 | 41–79 | 39–81 | 24–81 |
  ≤ 50 years | 46 (57.5%) | 3 (9.1%) | 4 (16.7%) | 53 (38.7%) |
  > 50 years | 34 (42.5%) | 30 (90.9%) | 20 (83.3%) | 84 (61.3%) |
MMR IHC pattern of losse | ||||
 MLH1/PMS2 | 37 (46.3%) | 19 (57.6%) | 7 (29.2%) | 63 (46%) |
 MSH2/MSH6 | 29 (36.3%) | 5 (15.2%) | 15 (62.5%) | 49 (35.8%) |
 MSH6 | 6 (7.5%) | 9 (27.3%) | 1 (4.2%) | 16 (11.7%) |
 PMS2 | 4 (5%) | 0 (0%) | 1 (4.2%) | 5 (3.6%) |
 MSH6 and PMS2 | 2 (2.5%) | 0 (0%) | 0 (0%) | 2 (1.5%) |
 Loss of all four MMR proteins | 2 (2.5%)c,d | 0 (0%) | 0 (0%) | 2 (1.5%) |
Colorectal cancer | ||||
 Tumor site, n (%) | ||||
  Proximal | 55 (68.8%) | – | – | – |
  Distal | 16 (20%) | – | – | – |
  Rectum | 9 (11.2%) | – | – | – |
 Tumor grade, n (%) | ||||
  Well differentiated | 8 (10%) | – | – | – |
  Moderately differentiated | 43 (53.8%) | – | – | – |
  Poorly differentiated | 26 (32.5%) | – | – | – |
  Undifferentiated | 1 (1.2%) | – | – | – |
  Unknown | 2 (2.5%) |  |  |  |
Histological type, n (%) | ||||
 Adenocarcinoma | 67 (83.8%) | – | – | – |
 Mucinous | 12 (15%) | – | – | – |
 Other | 1 (1.2%) | – | – | – |
Endometrial cancer | ||||
 FIGO staging, n (%) | ||||
  Stage 1 | – | 19 (57.6%) | – | – |
  Stage 2 | – | 8 (24.2%) | – | – |
  Stage 3 | – | 6 (18.2%) | – | – |
Histological type, n (%) | ||||
  Endometrioid | – | 30 (90.9%) | – | – |
  Clear cell | – | 2 (6.1%) | – | – |
  Carcinosarcoma | – | 1 (3%) | – | – |
Sebaceous skin tumor | ||||
 Tumor site, n (%) | ||||
  Head and neck | – | – | 14 (58.3%) | – |
  Trunk and limb | – | – | 10 (41.7%) | – |
Histological type, n (%) | ||||
  Sebaceoma | – | – | 1 (4.2%) | – |
  Sebaceous adenoma | – | – | 21 (87.5%) | – |
  Sebaceous carcinoma | – | – | 2 (8.3%) | – |